alitretinoin and Foot-Dermatoses

alitretinoin has been researched along with Foot-Dermatoses* in 8 studies

Trials

1 trial(s) available for alitretinoin and Foot-Dermatoses

Article	Year
Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study. The British journal of dermatology, 2016, Volume: 174, Issue:6 Palmoplantar pustulosis (PPP) is an inflammatory, debilitating skin disease. Topical drugs and systemic immunosuppressive agents are often ineffective. Previous uncontrolled studies have suggested that alitretinoin could be a meaningful treatment option for PPP.. The primary objective was to determine response to alitretinoin for the treatment of PPP based on the Palmoplantar Pustulosis Area and Severity Index (PPPASI) after 24 weeks of treatment.. A phase II, randomized, double-blind, placebo-controlled, multicentre study. Adult patients with PPP (with or without psoriasis) refractory to topical therapy and standard skin care were randomized 2:1 to alitretinoin 30 mg once daily or placebo for up to 24 weeks. The primary end point was PPPASI at week 24 (or the last visit in case of early withdrawal). Secondary end points included: percentage change from baseline in the modified Psoriasis Area and Severity Index (mPASI); percentage of patients with ≥ 50% or 75% improvement in PPPASI or mPASI scores from baseline; change in pustule count on the palms and soles; change in the Nail Psoriasis Severity Index and safety and tolerability assessments.. Thirty-three patients were randomized: 24 patients to alitretinoin 30 mg and nine to placebo. Overall, there were no significant differences between alitretinoin 30 mg and placebo for any end point. The safety profile was consistent with that seen in patients with chronic severe hand eczema refractory to potent topical corticosteroids.. Although the results were unexpected based on previous studies of alitretinoin in the treatment of PPP, this study provided no evidence to support further exploration of alitretinoin in the treatment of severe PPP. Topics: Administration, Cutaneous; Administration, Oral; Alitretinoin; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome; Tretinoin	2016

Article

Year

Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.

The British journal of dermatology, 2016, Volume: 174, Issue:6

Palmoplantar pustulosis (PPP) is an inflammatory, debilitating skin disease. Topical drugs and systemic immunosuppressive agents are often ineffective. Previous uncontrolled studies have suggested that alitretinoin could be a meaningful treatment option for PPP.. The primary objective was to determine response to alitretinoin for the treatment of PPP based on the Palmoplantar Pustulosis Area and Severity Index (PPPASI) after 24 weeks of treatment.. A phase II, randomized, double-blind, placebo-controlled, multicentre study. Adult patients with PPP (with or without psoriasis) refractory to topical therapy and standard skin care were randomized 2:1 to alitretinoin 30 mg once daily or placebo for up to 24 weeks. The primary end point was PPPASI at week 24 (or the last visit in case of early withdrawal). Secondary end points included: percentage change from baseline in the modified Psoriasis Area and Severity Index (mPASI); percentage of patients with ≥ 50% or 75% improvement in PPPASI or mPASI scores from baseline; change in pustule count on the palms and soles; change in the Nail Psoriasis Severity Index and safety and tolerability assessments.. Thirty-three patients were randomized: 24 patients to alitretinoin 30 mg and nine to placebo. Overall, there were no significant differences between alitretinoin 30 mg and placebo for any end point. The safety profile was consistent with that seen in patients with chronic severe hand eczema refractory to potent topical corticosteroids.. Although the results were unexpected based on previous studies of alitretinoin in the treatment of PPP, this study provided no evidence to support further exploration of alitretinoin in the treatment of severe PPP.

Topics: Administration, Cutaneous; Administration, Oral; Alitretinoin; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome; Tretinoin

2016

Other Studies

7 other study(ies) available for alitretinoin and Foot-Dermatoses

Article	Year
Alitretinoin: treatment for refractory palmoplantar keratoderma. The British journal of dermatology, 2016, Volume: 174, Issue:5 Topics: Administration, Oral; Alitretinoin; Dermatologic Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Treatment Outcome; Tretinoin; Young Adult	2016
Alitretinoin in the treatment of palmoplantar mycosis fungoides: a new and promising therapeutic approach. Clinical and experimental dermatology, 2015, Volume: 40, Issue:4 Topics: Alitretinoin; Antineoplastic Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome; Tretinoin	2015
Can median nail dystrophy be an adverse effect of alitretinoin treatment? Acta dermato-venereologica, 2014, Volume: 94, Issue:6 Topics: Alitretinoin; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Substitution; Eczema; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Nail Diseases; Nails, Malformed; Time Factors; Treatment Outcome; Tretinoin	2014
Successful treatment of recalcitrant chronic foot eczema with alitertinoin. Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:10 Topics: Alitretinoin; Chronic Disease; Eczema; Female; Foot Dermatoses; Humans; Middle Aged; Remission Induction; Tretinoin	2012
Case study 2--A 33-year-old female horse trainer with long-standing hand and foot eczema. Clinical and experimental dermatology, 2011, Volume: 36 Suppl Topics: Adult; Alitretinoin; Animal Husbandry; Animals; Dermatitis, Occupational; Dermatologic Agents; Female; Foot Dermatoses; Hand Dermatoses; Horses; Humans; Tretinoin	2011
Case study 3--A 41-year-old male with hyperkeratotic changes to the hands and feet. Clinical and experimental dermatology, 2011, Volume: 36 Suppl Topics: Adult; Alitretinoin; Dermatologic Agents; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Male; Tretinoin	2011
Case study 5--A 50-year-old female politician with long-standing chronic hand eczema affecting her quality of life. Clinical and experimental dermatology, 2011, Volume: 36 Suppl Topics: Alitretinoin; Chronic Disease; Dermatologic Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Politics; Quality of Life; Tretinoin	2011